EGFR and non-small cell lung carcinoma: In the 15 aforementioned randomized controlled trials, a total of 2257 patients with advanced EGFR-mutant nonsquamous NSCLC were allocated erlotinib or gefitinib monotherapy in control or experimental treatment arms.